During 1Q26, Burcon advanced meaningfully in its commercialization strategy. Within 90 days of commissioning its Galesburg facility, the Company achieved first commercial production of its next-generation Peazazz® C pea protein and debuted FavaPro™ fava protein. Initial shipments of Peazazz® C were completed during the quarter, supported by strong market reception and customer trials. Burcon also entered into a $6.8 million multi-year production agreement, underpinning its 2025 revenue target of $1–3 million. The Galesburg facility integrates Burcon’s proprietary protein technologies, enabling scalable, versatile production across multiple plant-based proteins. This operational flexibility positions the Company to meet evolving customer needs quickly and with consistent quality, while unlocking a total addressable pea protein market estimated at US$215 million to US$392 million.